<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D97B4909-9AD2-4885-A35F-6978F2F0287F"><gtr:id>D97B4909-9AD2-4885-A35F-6978F2F0287F</gtr:id><gtr:firstName>Elaine</gtr:firstName><gtr:surname>Soon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802261"><gtr:id>33195535-EF82-498B-B8F1-04475833874D</gtr:id><gtr:title>Loss of BMPR-II promotes oxidative stress and inflammation in pulmonary arterial hypertension</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802261</gtr:grantReference><gtr:abstractText>Pulmonary arterial hypertension is a devastating condition, typically affecting young women, which leads to death within three years of diagnosis without treatment. New treatments have improved symptoms but the overall outlook remains poor. The cause of this disease remained a mystery until the identification of genetic mutations in a receptor known as bone morphogenetic protein type II receptor, or BMPR-II. The identification of these mutations has provided the first real insight into the underlying cause of this condition. In Professor Morrell?s laboratory we are trying to establish the connection between a mutation in BMPR-II and the narrowing of blood vessels in the lung, which characterise pulmonary arterial hypertension. A potentially important observation is that reduced function of the BMPR-II receptor makes cells more susceptible to inflammation. Since inflammation in blood vessels is known to contribute to pulmonary hypertension, this research may provide a novel link between the genetic defect and the progression of disease. If we can understand the mechanism by which BMPR-II mutation causes inflammation we may be able to block this process. It would then be possible to develop new treatments for this condition using, for example, anti-inflammatory approaches that are already under development for other diseases.</gtr:abstractText><gtr:technicalSummary>Pulmonary arterial hypertension (PAH) is a devastating condition which affects predominantly young women. Death typically ensues from right heart failure within 3 years without modern treatments. Available treatments improve symptoms of breathlessness but survival remains poor. The identification of heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II receptor (BMPR-II) in familial pulmonary arterial hypertension (PAH) was a major advance in our understanding of this condition. Our laboratory and others have demonstrated that a reduction in BMP receptor signalling is a feature common to many forms of PAH, even in the absence of identifiable mutations in the BMPR2 gene. Thus the level of expression of BMPR-II appears central to PAH pathogenesis. Pro-inflammatory pathways have recently been implicated in the pathogenesis of PAH. My own studies have demonstrated that patients with familial and idiopathic PAH have increased circulating levels of cytokines. In preliminary studies we have shown that pulmonary artery smooth muscle cells (PASMCs) deficient in BMPR-II exhibit increased basal and transforming growth factor- stimulated cytokine expression, particularly interleukin-6 (IL-6) and IL-8. Based on compelling preliminary findings our hypothesis is that a loss of BMPR-II function impairs antioxidant pathways in PASMCs leading to activation of NF-kB and release of cytokines which contribute to the process of pulmonary vascular remodelling. The main aims of this study are to: (i) confirm that a loss of BMPR-II is associated with an increase in the activation of nuclear factor kappa- (NF-kB) signalling and the expression of pro-inflammatory cytokines in pulmonary artery smooth muscle cells (PASMCs); (ii) determine the role of autocrine release of cytokines on PASMC proliferation and migration; (iii) determine whether PASMCs lacking BMPR-II are deficient in their handling of reactive oxygen species and (iv) determine whether the mechanism for these effects involves an interaction between BMPR-II and antioxidant enzymes. These studies will use human and mouse PASMCs, including cells derived from patients with defined mutations in BMPR-II and controls. The approach will include in vivo studies in heterozygous knock-out mice deficient in BMPR-II and knock-in mice harbouring a known human mutation (R899X). This research will provide a novel link between the major genetic susceptibility to PAH and the role of inflammation in driving the vascular remodelling that characterises this condition. Since the lungs are uniquely susceptible to oxidative injury these studies may elucidate the lung specific nature of PAH as well as providing new opportunities for therapeutic intervention.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>203262</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Role of BMPR2 in iron metabolism</gtr:description><gtr:id>6963A239-4087-450E-BFB0-C662A8BE1D63</gtr:id><gtr:impact>The collaboration is ongoing and no publications have been accepted as yet.</gtr:impact><gtr:outcomeId>TmvFR2y3JPn-1</gtr:outcomeId><gtr:partnerContribution>Creati on of a liver specific bmpr2 deficient mouse to further characterise the role of bmpr2 in iron metabolism.</gtr:partnerContribution><gtr:piContribution>Initial investigations into the role of iron in PAH were made in a bmpr2+/- mouse model of PAH deprived of iron.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BTS Special Advisory Group for Pulmonary Vascular Disease</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B18D42B4-CE9F-4BF9-8067-FF1B1DBD8F1F</gtr:id><gtr:impact>Setting of SCE questions, planning guideline updates and screening of abstracts for BTS Winter meeting.</gtr:impact><gtr:outcomeId>58b81aca63feb0.99656115</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sackler studentship 2010</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Raymond and Beverly Sackler Foundation</gtr:fundingOrg><gtr:id>BC5F0085-D368-42BD-85F7-6C9FF3C00578</gtr:id><gtr:outcomeId>KPd3tgNQzmx</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>ATS/PAR</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>American Pulmonary Hypertension Association</gtr:fundingOrg><gtr:fundingRef>Nil</gtr:fundingRef><gtr:id>62117A39-7ADF-4136-A081-1078F3A8AD2C</gtr:id><gtr:outcomeId>JV2xcfA8ch1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLF Travel Award</gtr:description><gtr:end>2009-05-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>A551E540-63B8-4E7E-A3ED-273B10F359F4</gtr:id><gtr:outcomeId>oSG6hntukw2</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sackler studentshop 2011</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Raymond and Beverly Sackler Foundation</gtr:fundingOrg><gtr:id>281D6896-A264-47C9-AD39-1EAFD0D9D1C9</gtr:id><gtr:outcomeId>kuAsax1v88f</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AMS Clinical Lecturer Starter grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>2FC6125F-801B-40A2-BE82-57AA955F9D8B</gtr:id><gtr:outcomeId>56e063f51970f6.31163209</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sackler studentship 2009</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Raymond and Beverly Sackler Foundation</gtr:fundingOrg><gtr:id>139B85A1-99B3-46F3-9A1C-2CF59A7981EB</gtr:id><gtr:outcomeId>eMUWQnoRRNC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer Pulmonary Vascular Disease research grant</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>4C4FAC26-0D8E-4C13-86A2-44BF1ACCE273</gtr:id><gtr:outcomeId>Rf7PT91r3qm0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Clinical trial of tocilizumab in PAH patients. Trial currently in recruitment.</gtr:description><gtr:id>FB39F986-48A1-4C8F-A56B-E07EE92868A9</gtr:id><gtr:impact>As above.</gtr:impact><gtr:outcomeId>56e06504b9c4c4.63062014</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension (TRANSFORM-UK)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ADD810E1-9A1C-40FC-A611-CB3C2499E663</gtr:id><gtr:title>Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8aeaa46a53b7a6d9ad38fa32c147003"><gtr:id>e8aeaa46a53b7a6d9ad38fa32c147003</gtr:id><gtr:otherNames>Condliffe R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>pm_13059_29_22558516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67F15578-ED60-40FB-B26C-D141DDF21E94</gtr:id><gtr:title>BMPR-II mutations promote pulmonary arterial hypertension via a hyperinflammatory response.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>56e061b52e22b6.15930461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88CD30B5-A859-466C-AA83-13EA4F37A091</gtr:id><gtr:title>Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3bbe27015d9b0d2dedbe98dbf0e42a"><gtr:id>1b3bbe27015d9b0d2dedbe98dbf0e42a</gtr:id><gtr:otherNames>Ormiston ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13059_29_22832786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1374DC43-64A7-4D29-A059-E45D582CADA4</gtr:id><gtr:title>Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a99f16bc93214eac505199abaa3b0970"><gtr:id>a99f16bc93214eac505199abaa3b0970</gtr:id><gtr:otherNames>Crosby A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_13059_29_21659614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>370595BC-D548-4CAC-A095-C15CCAB75A79</gtr:id><gtr:title>Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_13059_29_21297151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB424940-F450-4F8F-B3FA-116C001C4230</gtr:id><gtr:title>Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>sn134w3FAeq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61F18A8D-8561-4086-BCF6-045C59A5EE9B</gtr:id><gtr:title>Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56e061b55155c6.45197886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FFB2831-3916-4C79-94FD-14E779A63DCD</gtr:id><gtr:title>Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>pm_13059_29_22034610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>675F1BFF-8E32-41AB-84FD-46C8338D23DA</gtr:id><gtr:title>Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d937f5f0be2511cd86725eea834e5c4c"><gtr:id>d937f5f0be2511cd86725eea834e5c4c</gtr:id><gtr:otherNames>Toshner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_13059_19_19628780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A909BD-AE77-45F5-8931-85F0C073E406</gtr:id><gtr:title>Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.</gtr:title><gtr:parentPublicationTitle>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0ca8637fc56144623b946d1038b3c86"><gtr:id>a0ca8637fc56144623b946d1038b3c86</gtr:id><gtr:otherNames>Toshner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-2498</gtr:issn><gtr:outcomeId>pm_13059_29_20227301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CD924C5-E00E-4778-8579-A9DC1E27FEFB</gtr:id><gtr:title>Key Clinical Topics in Cardiology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b81cccba67b2.91923498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E36C2C2E-B9D6-4910-84E0-39831793046A</gtr:id><gtr:title>Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a99f16bc93214eac505199abaa3b0970"><gtr:id>a99f16bc93214eac505199abaa3b0970</gtr:id><gtr:otherNames>Crosby A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56e061b4d8f3f1.59552897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA49AA1C-92DA-4AB5-9441-0E1636D447A2</gtr:id><gtr:title>(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5d5eeb1acb0e84c290e1858e1e7e2ba"><gtr:id>d5d5eeb1acb0e84c290e1858e1e7e2ba</gtr:id><gtr:otherNames>Hagan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>pm_13059_29_22530099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0029ED9-36FD-4382-8692-5E0D93EFFF08</gtr:id><gtr:title>Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4c139084ccbf25f1aa6ed9b69f5df80"><gtr:id>a4c139084ccbf25f1aa6ed9b69f5df80</gtr:id><gtr:otherNames>Caruso P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>pm_13059_29_20110569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09F61D41-0C31-4E8F-9A3B-0F82CF9D4A0D</gtr:id><gtr:title>Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>K83pGMZLUq4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D90A0CAA-07EF-4426-8EC4-A903C0E79280</gtr:id><gtr:title>Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d937f5f0be2511cd86725eea834e5c4c"><gtr:id>d937f5f0be2511cd86725eea834e5c4c</gtr:id><gtr:otherNames>Toshner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_13059_29_22362857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DDFC788-FFFA-4A8A-A81D-7026F14AEA09</gtr:id><gtr:title>Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>pm_13059_29_21329849</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802261</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>